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Relational machine learningObjective: Electronic health records (EHR) offer medical and pharmacogenomics research unprecedented
opportunities to identify and classify patients at risk. EHRs are collections of highly inter-dependent
records that include biological, anatomical, physiological, and behavioral observations. They comprise
a patient’s clinical phenome, where each patient has thousands of date-stamped records distributed
across many relational tables. Development of EHR computer-based phenotyping algorithms require time
and medical insight from clinical experts, who most often can only review a small patient subset repre-
sentative of the total EHR records, to identify phenotype features. In this research we evaluate whether
relational machine learning (ML) using inductive logic programming (ILP) can contribute to addressing
these issues as a viable approach for EHR-based phenotyping.
Methods: Two relational learning ILP approaches and three well-knownWEKA (Waikato Environment for
Knowledge Analysis) implementations of non-relational approaches (PART, J48, and JRIP) were used to
develop models for nine phenotypes. International Classiﬁcation of Diseases, Ninth Revision (ICD-9)
coded EHR data were used to select training cohorts for the development of each phenotypic model.
Accuracy, precision, recall, F-Measure, and Area Under the Receiver Operating Characteristic (AUROC)
curve statistics were measured for each phenotypic model based on independent manually veriﬁed test
cohorts. A two-sided binomial distribution test (sign test) compared the ﬁve ML approaches across phe-
notypes for statistical signiﬁcance.
Results: We developed an approach to automatically label training examples using ICD-9 diagnosis codes
for the ML approaches being evaluated. Nine phenotypic models for each ML approach were evaluated,
resulting in better overall model performance in AUROC using ILP when compared to PART (p = 0.039),
J48 (p = 0.003) and JRIP (p = 0.003).
Discussion: ILP has the potential to improve phenotyping by independently delivering clinically expert
interpretable rules for phenotype deﬁnitions, or intuitive phenotypes to assist experts.
Conclusion: Relational learning using ILP offers a viable approach to EHR-driven phenotyping.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Medical research attempts to identify and quantify relation-
ships between exposures and outcomes. A critical step in thisprocess is subject characterization or phenotyping [1–4]. Without
rigorous phenotyping, these relationships cannot be properly
assessed, leading to irreproducible study results and associations
[1]. With the proliferation of electronic health records (EHRs), com-
puterized phenotyping has become a popular and cost effective
approach to identify research subjects [5]. The EHR contains highly
inter-dependent biological, anatomical, physiological, and behav-
ioral observations, as well as facts that represent a patient’s
diagnosis and medical history. Typically, developing EHR-based
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selecting patients from the EHR and then reviewing the selections
to identify classiﬁcation features that succinctly categorize them
into study groups [6]. This process is time consuming [1] and relies
on expert perceptions, intuition, and bias. Due to time limitations,
experts carefully examine a small fraction of available EHR data for
phenotype development. In addition, due to both the enormous
volume of data found in the EHR and human bias, it is difﬁcult
for experts to uncover ‘‘hidden’’ relationships or ‘‘unseen’’ features
relevant to a phenotype deﬁnition. The result is a serious temporal
and informative bottleneck when constructing high quality
research phenotypes.
The use of machine learning (ML) as an alternative EHR-driven
phenotyping strategy has been limited [7–13]. Previous ML studies
have applied a variety of standard approaches (e.g. SMO, Ripper,
C4.5, Naïve Bayes, Random Forest via WEKA, Apriori, etc.) to coded
EHR data in order to identify relevant clinical features or rules for
phenotyping. All of these ML methods were propositional, that is,
they used data that were placed into a single ﬁxed length, ﬂat fea-
ture table for analysis.
Data from EHRs pose signiﬁcant challenges for such proposi-
tional ML and data mining approaches, as previously noted [14].
First, EHRs may include reports on thousands of different condi-
tions across several years. Knowing which features to include in
the ﬁnal feature table and how they relate often requires clinical
intuition and a considerable amount of time spent by experts (phy-
sicians). Second, EHR data are noisy. For example, in some cases
diagnostic codes are assigned to explain that laboratory tests are
being done to conﬁrm or eliminate the coded diagnosis, rather than
to indicate that the patient actually has the diagnosis. Third, EHR
data are highly relational and multi-modal. Known ﬂattening tech-
niques, such as computing summary features or performing a data-
base join operation, can usually result in loss of information [15].
For example, the Observational Medical Outcomes Partnership
(OMOP) phenotypes lymphoma as either a temporal sequence ini-
tiated with a biopsy or related procedure, followed within 30 days
by a 200-202 International Classiﬁcation of Diseases, Ninth Revi-
sion (ICD-9) code, or a 200-202 ICD-9 code followed within 30 days
by radiation or a chemotherapeutic treatment [16]. Verifying such
a rule requires using data from three different tables and compar-
ing the respective event times. Thus, a ﬂat feature representation
for learning ignores the structure of EHR data and, therefore, does
not suitably model this complex task. Arguably, more advanced
data structures such as trees, graphs, and propositional reasoners
can handle the EHR data structure, but these approaches assume
a noise free domain and cannot deal with missing or disparate data
often present in the EHR [17,18].
Inductive logic programming (ILP), a subﬁeld of relational
machine learning, addresses the complexities of dealing with
multi-relational EHR data [15] and has the potential to learn fea-
tures without the existential perceptions of experts. ILP has been
used in medical studies ranging from predictive screening for
breast cancer [19,20] to predicting adverse drug events
[14,21,22] or adverse clinical outcomes [23–25]. Unlike rule induc-
tion and other propositional machine learning algorithms that
assume each example is a feature vector or a record, ILP algorithms
work directly on data distributed over different EHR tables. The
algorithmic details of leading ILP systems have been thoroughly
described [26,27] and are summarized in the methods section.
To our knowledge, this represents the ﬁrst use of ILP for pheno-
typing. The work of Dingcheng et al. in phenotyping type 2 diabe-
tes [11] is similar to ours in that it also uses a rule-based data-
mining approach (Apriori association rule learning algorithm)
which shares the advantage of learning rules for phenotyping that
are easily understood by human users. The primary difference
between the two approaches is our use of ILP to directly learn fromthe extant tables of the EHR versus Apriori, which must learn from
data conﬂated into a single table. This paper compares the use of
ILP for phenotyping to other well-known propositional ML
approaches.
As a ﬁnal contribution, we introduce several novel techniques
used to better automate the learning process and to improve
model performance. These techniques fall into three categories:
(1) selection of training set examples without expert (physician)
involvement to provide supervision for the learning activities; (2)
left-censoring of background data to identify subgroups of patients
that have similar features denoting the phenotype; and (3) infusing
borderline positive examples to improve rule prediction.2. Methods
The Marshﬁeld Clinic Research Foundation’s Institutional
Review Board approved this study. The goal of our research was
twofold: (1) to evaluate the performance of ILP for EHR-driven
phenotyping and compare it to other ML and data mining
approaches; and (2) to develop methods that reduce expert (phy-
sician) time and enhance attribute awareness in the EHR-driven
phenotyping process. The methods presented in this paper were
applied to nine disease-based phenotypes to demonstrate the util-
ity of the ILP approach.
2.1. Data source, study cohort, and phenotype selection
Marshﬁeld Clinic’s internally developed CattailsMD EHR-
Research Data Warehouse (RDW) was used as the source of data
for this investigation. RDW data from 1979 through 2011, includ-
ing diagnoses, procedures, laboratory results, observations, and
medications for patients residing in a 22 ZIP Code area, were de-
identiﬁed and made available for this study. The phenotypes used
in this investigation were selected based on the availability of
manually validated (case-control status) cohorts and include:
acute myocardial infarction, acute liver failure, atrial ﬁbrillation,
cataract, congestive heart failure, dementia, type 2 diabetes, dia-
betic retinopathy and deep vein thrombosis [24,25,28]. The RDW
was used to select training cohorts for each phenotype. These
training cohorts were used to guide phenotype model develop-
ment for all of the ML approaches. The manually validated cohorts
(henceforth referred to as testing subjects or test cohorts) were
used to test the phenotype models by providing model perfor-
mance comparison statistics. An overview of the study design is
presented in Fig. 1.
2.2. Identiﬁcation of training set examples
The ability to accurately identify training examples to guide a
supervised machine learning task is critical. Several ML studies
have used experts (physicians) to review medical records to clas-
sify patients into the positive (POS) (patients with a condition or
exposure) and NEG (patients without the condition) example cate-
gories [7,9] or used pre-existing validated cohorts representing
POS and NEG training examples. A secondary goal of this research
was to develop methods that could reduce expert (physician) time
required for EHR-driven phenotyping; thus, it would be optimal to
develop an approach for selecting training examples that did not
require physician input or pre-existing categorized training
examples.
A recent study by Carroll et al. [7] evaluated support vector
machines for phenotyping rheumatoid arthritis and demonstrated
the utility of ICD-9 CM diagnostic codes when characterizing
research subjects. This knowledge coupled with our past pheno-
typing experience [28] prompted the use of ICD-9 codes as a
Fig. 1. Overview of data preparation and analysis processes. Positive (POS), negative (NEG) and borderline positive (BP) training examples are selected using the electronic
health record (EHR) data. Inductive logic programming (ILP) background knowledge (EHR data) and propositional machine learning (ML) feature tables are created and used
by each of the respective ML methods. Manually veriﬁed test subject data is prepared similar to training data and is used to create performance statistics that are used to
compare ML approaches.
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examples for model building. A sampling frame of patients with
at least 15-20 ICD-9 codes spanning multiple days was used to
deﬁne the surrogate POS cohort. From this cohort, we randomly
selected a subset for model building (henceforth referred to as
the POS training set). We required multiple ICD-9 codes based on
the assumption that a patient who truly exhibits one of the pheno-
types of interest will receive continuing care, in contrast with a
patient who does not exhibit the phenotype but may have a small
number of relevant ICD-9 codes in their record for administrative/
billing reasons. A working cutoff for the number of codes was
established as follows. The frequency distribution of patient num-
bers of ICD-9 codes was determined. Ranking patients from highest
to lowest number of ICD-9 diagnoses, we targeted between 1000
and 1500 patients with highest ICD-9 counts to be labeled as
POS, and similarly placed an upper limit on the training set size
(refer to Table 1) to facilitate timely data transfers between the
RDW and the machine learning environment.
For each selected POS in our training set, we randomly selected
a NEG (ICD-9 code of the phenotype was not present in patient’s
medical history) from a pool of similar age and gender matched
patients (Fig. 2 provides overview of the sampling strategy).
Patients with only a single diagnosis or multiple diagnoses on
the same day were labeled as borderline positive examples (BPs).
The use of these classiﬁcations will be described later. Refer to
Table 1 for details on POS, NEG and BP numbers for each
phenotype.
2.3. Identiﬁcation of testing set examples
Earlier in this discussion we indicated that we had access to
manually validated phenotyped cohorts. We chose to use these
cohorts for testing the performance of the phenotype models
rather than for model training or development. Two testing cohorts
(congestive heart failure [CHF] and acute liver injury [ALI]) were
constructed in parallel to this investigation. A similar manual chart
review and classiﬁcation process was used for each phenotype to
construct the testing cohorts. In general, trained research coordina-
tors manually reviewed charts and classiﬁed a list of patients as
either POS or NEG. A second research coordinator independently
reviewed a sample of records completed by the ﬁrst reviewer(usually a 5–10% sample or a ﬁxed sample size for the larger
cohorts) for quality assurance. A board-certiﬁed physician resolved
disagreements or questions surrounding the classiﬁcations of
subjects. For example, there were three noted disagreements in
the ALI abstraction that were resolved in this manner.
2.4. Machine learning phenotyping approaches
2.4.1. ILP approach
ILP addresses the problem of learning (or inducing) ﬁrst-order
predicate calculus (FOPC) rules from a set of examples and a data-
base that includes multiple relations (or tables). Most work in ILP
limits itself to non-recursive Datalog [29], a subset of FOPC equiv-
alent to relational algebra expressions or SQL queries, which differ-
entiate positive examples (cases) from negative examples (control
patients) given background knowledge (EHR data). A database with
multiple tables is represented as an extensional Datalog program,
with one predicate for each table and one fact for each tuple
(record) in each table. The rules that we learn are equivalent to
SQL queries; hence, a rule can be thought of as deﬁning a new table
and a set of rules as deﬁning a new view of the database.
Our work used Muggleton’s Progol algorithm [30] as imple-
mented in Srinivasan’s Aleph system [31]. Progol applies the idea
that if a rule is useful, it must explain (or cover) at least one exam-
ple. Thus, instead of blindly generating rules, Progol ﬁrst looks in
detail at one example, and it only constructs rules that are guaran-
teed to cover that example. The beneﬁt of using this approach is
that instead of having to generate rules for all conditions, drugs,
or labs in the EHR, it can generate rules for a much smaller number
of conditions.
The Aleph implementation uses the data connected to an exam-
ple to construct rules. The head of the rule always refers to the
patient. The body refers to facts for that speciﬁc patient. These
‘‘ground’’ rules are then generalized by introducing variables au
lieu of individual patients or of speciﬁc time points. Shorter rules
are constructed ﬁrst. In this study, we used breadth-ﬁrst search
over a fast-growing search space, so the major limitation is the
number of elements that we combine and still achieve acceptable
performance. This is rarely more than 4. It is possible to explore
longer rules, often up to 10 or more, by using greedy search or ran-
domized search instead of a complete search.
Table 1
Phenotypes and sampling frame.
Phenotypes ICD-9 diagnosis codes Minimum # ICD-9
codes used to select
training POSb
Pool of
available POSb,c
# Training
POSb,d
# Training
NEGd,e
# Training
borderline
positivesd
Acute myocardial infarction 410.a 20+ 4364 1500 1500 460
Acute liver injury 277.4, 572.1–4, 573.1–4, 576.8, 782.4, 782.8,
790.40
15+ 7393 314 314 314
Atrial ﬁbrillation 427.31 20+ 6619 1000 1000 489
Cataracts 366.00–366.9 & 743.30–743.34 20+ 19,150 1000 1000 1000
Congestive heart failure 428a 20+ 8280 1000 1000 750
Dementia 290.00, 290.10, 290.11, 290.12, 290.13, 290.3,
290.20, 290.0, 290.21, 291.2, 292.82, 294.1,
294.11, 294.10, 294.20, 294.21, 331.19, 331.82,
290.40, 290.41, 290.42, 290.43
20+ 4139 1126 1126 657
Type 2 diabetes 250.a 20+ 10,899 1500 1500 1000
Diabetic retinopathy 362.01, 362.10, 362.12, 362.82, 362.84, 362.85,
362.07, 362.02, 362.03, 362.04, 362.05, 362.06
20+ 2525 606 606 606
Deep vein thrombosis 453.a 20+ 4140 1000 1000 658
Note: Phenotype models were constructed for nine conditions. Training positive and borderline positive examples were identiﬁed using ICD-9 diagnosis codes. Negative
training examples had no ICD-9 diagnosis code.
a Include all decimal digits.
b POS indicates positive examples.
c Includes all patients with at least one ICD-9 diagnosis code.
d Randomly selected.
e NEG indicates negative examples.
Fig. 2. (A) Inductive logic programming (ILP) uses retrospective data to predict disease outcomes. (B) Phenotyping with ILP uses data collected after the incident date (of a
condition), to predict features that a subgroup may be sharing that are representative of a phenotype.
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example (referred to as a seed) not yet explained by any rule. In
the EHR domain, the positive example is a patient that has the
exposure or medical condition of interest. (2) Searches the data-
base for data directly related to the example. In the case of an
EHR, this means collecting all diagnoses, prescriptions, lab results,
etc., for the example patient. (3) Generates rules based on the
patient. The rule will be constructed from the events of the chosen
patient’s history (referred to as clauses) generalized to explain
other patients. This is achieved by replacing the references to the
actual patient and temporal data with variables. The resulting rule(with variables) is applied to the training examples (both positive
and negative) using the EHR data to identify patients that can be
explained by the rule. (4) In practice, ILP must deal with inconsis-
tent and incomplete data; hence, it uses statistical criteria based on
the number of positively and negatively explained examples to
determine the quality of the rule. Two simple criteria that are often
used to score rules are precision (the fraction of covered examples
that are positive, also called the positive predictive value) or the
number of positive examples minus the number of negative exam-
ples covered by the clause, known as coverage. (5) The procedure
stops when it ﬁnds a good rule, and the examples explained by
264 P.L. Peissig et al. / Journal of Biomedical Informatics 52 (2014) 260–270the new rule are removed. If no more examples remain, learning is
complete. Otherwise, the process is repeated on the remaining
examples. Appendix A provides a more detailed introduction on
ILP to assist readers’ understanding.
2.4.1.1. Traditional ILP use. ILP usage in the medical domain has
focused on predicting patient outcomes [14,19–22]. Supervision
for the prediction task comes frompositive examples (POS—patients
with a medical outcome) and negative examples (NEG—patients
without the medical outcome), given some common exposure. For
example, to develop a model that will predict diabetic retinopathy
(DR), given a patient has diabetes, the supervision comes in the form
of POS (diabetic patients that have DR) and NEG (diabetic patients
without DR). EHR data collected before the DR occurrence is used
to build amodel to predictwhether a diabetic patient is at future risk
for DR (refer to Fig. 2A).
2.4.1.2. ILP for phenotyping. ILP applied to the phenotyping task
uses a similar approach, but in a reversed manner. For example,
when phenotyping we should not assume that we know all the
clinical attributes that are needed to succinctly identify patients
with a given phenotype (e.g., diabetes). Suppose we do not know
in advance that diabetes is associated with elevated blood sugar.
The POS and NEG cannot be selected as training examples based
on elevated blood sugar, because it is not yet known that elevated
blood sugar is an indicator for diabetes. Instead, the problem can
be addressed by selecting training examples based on the desired
phenotype or disease outcome (diabetes) and then running ILP
with EHR data ﬁltered by dates occurring on or after the ﬁrst diag-
nosis (refer to Fig. 2B). This seems counter-intuitive, because we
are training on patients with data obtained after diabetes is diag-
nosed in order to identify the common features of the phenotype
(diabetes). The features (or ILP rules) can then be applied to retro-
spective EHR data to select (or phenotype) unclassiﬁed patients. In
addition, if we can identify diabetic patients based on similar med-
ical features existing after the initial diagnosis, we may also be able
to uncover unknown (unbiased) features that further deﬁne the
phenotype.
2.4.1.3. Constructing background knowledge for ILP. Background
knowledge (EHR data) for phenotyping was created by selecting
coded ICD-9 diagnosis, medication, laboratory, procedure, and
biometric observation measurement records from the EHR. A cen-
sor date, representing the initial diagnosis date of the phenotype,
was determined for each POS and borderline positive (BP) example
(BP will be explained in the following section). All EHR background
knowledge recordswere labeled as before or after, based on the rela-
tionship of the event date (date of diagnosis, procedure, lab, ormed-
ication) to the censor date (refer to Fig. 3). Before records were
labeled if they occurred 5 years to 30 days before the censor date.Fig. 3. Censoring data to support inductiveWe used 30 days before the censor date, because we did not want
to include EHR facts that might be associated with diagnosing the
phenotype condition. After records were labeled if they occurred
in the period from less than 30 days before the censor date through
5 years after the censor date. EHR background knowledge records
for each NEG were similarly labeled as before or after based on the
censor date of the corresponding POS (since NEGs have no incident
diagnosis date). All EHR background knowledge records were for-
matted for Aleph ILP system software. The detailed methods sur-
rounding background ﬁle creation can be found in Appendix B-3.
Appendix C provides detailed examples of diagnosis, lab, gender,
drug, procedure, vitals and symptom record formatting for Aleph.
To summarize, a ‘‘b’’ is attached to the beginning of the patient_id
(ﬁrst variable in the parentheses) to indicate a before record (i.e.
vitals(‘b222aaa222’,68110,’Blood Pressure Diastolic’,’60’). There is
no preﬁx used when formatting the after record (i.e. vital-
s(‘222aaa222’,78110,’Blood Pressure Diastolic’,’60’).
2.4.1.4. ILP scoring functions. Scoring functions in Aleph and other
ILP systems evaluate the quality of a rule and thus, are fundamen-
tal to the learning process. We tested two different scoring func-
tions with Aleph [31]. The ﬁrst scoring function follows standard
ILP practice and was (POS(after)  NEG(after)), where POS(after)
denotes positive examples that use EHR data after the censor
date and NEG(after) denotes negative examples that use EHR data
after the censor date (Fig. 3). Simultaneously, we evaluated
(POS(after)  (NEG(after) + POS(before))), in which POS(before) denotes
positive examples that use EHR records before the censor date
and POS(after) and NEG(after) are as in the previous example. Early
on we found that diagnoses tended to ‘‘follow’’ patients over time.
The scoring function mimics an epidemiology research method
called Case-Crossover study design, where each case serves as its
own control and allows for the detection of differences from one
time period to another [32]. In our example, the later scoring func-
tion helps to identify differences in medical events between
POS(after) and POS(before) time periods, thus highlighting new medi-
cal events that occurred after the initial diagnosis but not before.
The cost function (POS(after)  (NEG(after) + POS(before))) was found
to improve model performance and accuracy over the initial scor-
ing function. Henceforth, this function will be referred to as ILP-1.
From previous work, we found that using the ILP-1 scoring func-
tion tended to create rules that could differentiate the POS and
NEGs based on ICD-9 codes relatively well, but often failed to pro-
vide more speciﬁc rules that could discriminate borderline POS and
NEG examples. To further discriminate and improve the rules, we
infused the NEGs with subjects that we considered borderline pos-
itives (BPs). BPs are examples of patients that have one relevant
diagnosis code, but not two, or several diagnoses on the same
day with no subsequent follow-up. BPs are problematic because
subjects may (or may not) have the medical diagnosis. This islogic programming scoring functions.
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tice to justify laboratory tests or procedures rather than to deﬁne
that a patient has the diagnosis. BPs likely include patients that
do not have the phenotype condition and by adding them to the
NEGs, we increase the precision of the learned rules. The scoring
function used to support the infusion of BPs into the NEGs is:
(POS(after)  (NEG(after) + POS(before) + BPs(after))). Henceforth, this
function will be referred to as ILP + BP.
We used a 1:1 ratio of POS to NEG while building the phenotype
model. Initially, we limited the number of POS and NEG to the
maximum number of BPs available (this was done for ALI and dia-
betic retinopathy phenotypes). Later, after completing a sensitivity
analysis to determine the optimal percent of BPs to add to the
NEGs (e.g., 25%, 50%, 75%, or 100%), we increased POS and NEG
training sets selection to accommodate the maximum subject limit
between 3–4000. The number of BPs used in each study was deter-
mined by either the availability of BPs in the cohort, or the number
of BPs could not exceed the number of NEG subjects in the training
set. Refer to Table 1 for the exact number of diagnoses used to
select training examples and the numbers of POS, NEG, and BPs
present in each phenotype training set.
2.4.1.5. ILP conﬁguration. ILP was adapted for phenotyping by
adjusting Aleph parameters reﬂecting the following beliefs: (1)
accepted rules should cover very few, ideally zero, negative exam-
ples; (2) rules that succeed on very few examples tend to over ﬁt (a
useful heuristic is that a rule is only acceptable when it covers at
least 20 examples); and (3) search time heavily depends on the
maximum number of rules that are considered for each seed.
Because of the high run-time for relational learning and the large
number of parameters, as well as to keep the process as simple
and generalizable as possible, we did not tune, but rather chose a
single set of parameter settings and applied them to all pheno-
types. We were careful to avoid the pitfall of trying many combina-
tions of parameter settings and then selecting the one that gives
the best results on the test set. We instead chose to use the follow-
ing settings which had shown good performance in previous appli-
cations: noise = 1, minpos = 80, minacc = 80, clause length = 4,
caching = false, i = 3, record = true and nodes = 1,000,000.
Using the cataract phenotype as an example, we have presented
a detailed description of our methods in Appendix B and made
available examples of record formats. Appendix C has examples
of the scripts and conﬁguration ﬁles (cat.b – ﬁle that contains the
parameters for running Aleph and runAleph.sh – a script that initi-
ates the Aleph phenotype model building session). Appendix D has
examples of ILP rules created for the cataract phenotype using ILP-
1 and ILP + BP ML approaches.
2.4.2. Propositional machine learning approaches
We selected two popular ML classiﬁers available in the widely
used Waikato Environment for Knowledge Analysis (WEKA) soft-
ware [33], after conducting a sensitivity analysis (using several
ML classiﬁers), to determine the highest performing approaches
based on area under the receivers operating characteristics curve
(AUROC). Using atrial ﬁbrillation as the phenotype, we compared:
Random Forest (AUROC = 0.682), SMO (0.506), PART (0.772), and J48
(0.772). From this analysis, we selected J48 and PART for use in the
ILP comparison. J48 is based on a Java implementation of the well-
known decision tree classiﬁer C4.5 [34] and PART, is the Java imple-
mentation of a rule based classiﬁer based on Classical and Regres-
sion Tree [35]. We also selected JRIP, the WEKA implementation of
the propositional rule learner Repeated Incremental Pruning to
Produce Error Reduction (RIPPER) [36]. The RIPPER implementa-
tion is similar to ILP, except that it assumes that each example is
a feature vector or record versus ILP algorithms work directly on
data distributed over multiple tables.2.4.2.1. Feature table creation. A feature table consisting of the same
POS and NEG examples used in ILP phenotype model building was
created and used by the propositional ML approaches for each phe-
notype. A record for each subjectwas constructed using information
obtained from the EHR. Each unique occurrence of a diagnosis, lab-
oratory result (categorized as ‘above’, ‘within’ or ‘below’ the normal
range), medication, or procedure was identiﬁed as a feature. Fre-
quencies of occurrence were calculated for each feature by subject.
Because of the large size of the feature table, we only used features
that were shared by more than 0.25% of the training subjects. In
other words, features were included if more than two or three sub-
jects (depending on phenotype) had the feature. The same features
identiﬁed for the training sets were used as features for the valida-
tion/test examples. For details refer to Appendix B.7.2.5. Analysis
Phenotyping model performance measurements were calcu-
lated using the number of correctly classiﬁed testing subjects. Con-
tingency tables were used to calculate accuracy, precision, recall
(the true positive rate, also called sensitivity), and F-Measure
(deﬁned as 2  [(recall  precision)/(recall + precision)]) statistics
for the ILP models. WEKA, version 3.6.9, automatically calculated
those statistics along with Receiver Operator Characteristic (ROC)
curves and area under the ROC curve (AUROC), for the proposi-
tional ML methods (J48, PART, and JRIP). To associate the probabil-
ities of AUROC and construct ROC curves for the ILP models, we
built a feature table using the ILP rules as features. A binary code
indicating if a subject met (or not), the rule criteria was assigned
for each feature by subject in the testing cohort. The Bayes Net-
Tan classiﬁer, as implemented in WEKA, was used to calculate
AUROC using the ILP features (rules) for each phenotype model
[37]. Such use of a Bayesian network to combine relational rules
learned by ILP is a popular approach used in statistical relational
learning to gain ROC curves and AUROC [15].
Signiﬁcance testing using a two-sided sign test (binomial distri-
bution test) at 95% conﬁdence was used to evaluate model sensi-
tivity when adding varying percentages of BPs (25%, 50%, 75%,
and 100%) to NEGs in the ILP + BP scoring function. Discordant clas-
siﬁcations of POS and NEG were obtained for each ILP approach
comparison and then similar signiﬁcance testing conducted.
To assess the difference in overall ML approach performance,
we counted the number of wins for a ML approach across pheno-
types and compared it to the number of wins for the comparison
ML approach. Signiﬁcance testing was done using a two-sided sign
test (binomial distribution test) at 95% conﬁdence, to evaluate a
difference in overall model performance between any of the ILP-
1, ILP + BP, PART, J48, and JRIP models.3. Results
The sampling frame used for the selection of all phenotype
training sets consisted of 113,493 subjects. Table 1 provides the
number of POS, NEG, and BP training subjects randomly selected
and used for the development of each phenotype model. Training
set sizes for both POS and NEG examples ranged from 314 (acute
liver injury) to 1500 (acute myocardial infarction and type 2
diabetes).
There was no signiﬁcant difference detected in overall model
performance when adjusting the BP percentages (between 25%,
50%, 75%, and 100%) for the ILP + BP scoring function. We found
that adding BP examples to the scoring function yielded more
descriptive rules for all phenotypes. For example, using atrial ﬁbril-
lation, a single rule having the presence of ICD-9 code ‘427.31’
(atrial ﬁbrillation) was learned by the ILP-1 approach. Using the
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rules, which included a combination of diagnoses, labs, procedures,
medications, and age. For consistency in reporting results, hence-
forth we will use ILP + BP with the contribution of 50% BPs.Table 2
Validation-testing sample characteristics.
Phenotypes Total number Mean
POSa NEGb Female (%) Agec
Acute myocardial infarction 363 158 199 (38.2%) 73.8
Acute liver injury 44 6 23(46%) 69.3
Atrial ﬁbrillation 36 35 31 (44%) 79.8
Cataracts 244 110 210 (59.32%) 75.2
CHF 60 36 51 (52%) 70
Dementia 303 70 203 (54.4%) 84
Type 2 diabetes 113 52 99 (60%) 67
Diabetic retinopathy 40 46 39 (45.4%) 71.6
Deep vein thrombosis 217 870 614 (56%) 76
Note: Phenotype models were validated using these validation cohorts.
a POS indicates positive examples.
b NEG indicates negative examples.
c Mean age calculated by (year of data pull (2012) – birth year).
d Years follow-up calculated by determining difference between ﬁrst and last diagnos
Table 3
Phenotype model validation results by phenotype.
Phenotype
Acute myocardial
infarction
Acute liver
injury
Atrial
ﬁbrillation
Cataract
Accuracy
ILP-1a 0.800 0.600 0.775 0.890
ILP + BPb 0.810 0.640 0.732 0.898
PARTc 0.775 0.660 0.775 0.879
J48d 0.785 0.700 0.775 0.822
JRIPe 0.791 0.780 0.775 0.879
Precision
ILP-1a 0.863 0.929 0.700 0.865
ILP + BPb 0.877 0.906 0.689 0.877
PARTc 0.790 0.848 0.824 0.877
J48d 0.797 0.829 0.824 0.819
JRIPe 0.869 0.902 0.700 0.904
Recall
ILP-1a 0.850 0.591 0.972 0.996
ILP + BPb 0.850 0.659 0.860 0.992
PARTc 0.755 0.660 0.775 0.879
J48d 0.785 0.700 0.755 0.822
JRIPe 0.824 0.841 0.972 0.922
F-Measure
ILP-1a 0.856 0.722 0.813 0.926
ILP + BPb 0.879 0.763 0.795 0.939
PARTc 0.788 0.719 0.765 0.877
J48d 0.789 0.747 0.765 0.820
JRIPe 0.794 0.798 0.765 0.878
AUROCh
ILP-1 + BNTf 0.769 0.752 0.772 0.893
ILPBP + BNTg 0.831 0.701 0.774 0.873
PARTc 0.788 0.716 0.772 0.842
J48d 0.722 0.619 0.722 0.783
JRIPe 0.769 0.587 0.772 0.852
Bolded numbers indicate highest score between phenotyping methods.
Note: Phenotype model accuracy measurements were calculated for each scoring func
examples.
a ILP-1: inductive logic programming with using POS(after)  (NEG(after) + POS(befor
b ILP + BP: inductive logic programming + borderline positives using POS(after)  (NEG
c PART: Java implementation of a rule based classiﬁer in WEKA.
d J48: Java implementation of C4.5 classiﬁer available in WEKA.
e JRIP: Java implementation of RIPPER classiﬁer available in WEKA.
f ILP-1 + BNT: BayesNet-Tan using ILP classiﬁcation rules.
g ILPBP + BNT: BayesNet-Tan using ILP + BP classiﬁcation rules.
h AUROC: area under receiver operating characteristics curve.Table 2 provides descriptive information on the phenotype test-
ing cohorts. The POS and NEG testing cohorts tended to be older
(>65 years of age) and similar with respect to years of follow-up
and ICD-9 diagnosis counts.Years followup4(St Dev) ICD-9 diagnosis count (St Dev)
POSa NEGb POSa NEGb
37.9 (9.7) 33.5 (12.2) 1848 (1475) 1384 (1304)
34.9 (10.6) 35.2 (10.0) 1880 (1568) 2550 (951)
29.2 (13.1) 31.7 (14.5) 1345 (811) 1468 (1100)
39.7 (9.8) 37.9 (11.2) 1395 (1004) 864 (616)
35.4 (10.0) 26.1 (13.8) 1614 (1184) 623 (647)
36.9 (11.3) 37.4 (8.64) 1579 (980) 1438 (1067)
36.3 (12.3) 34.0 (13.6) 1447 (781) 925 (781)
35.1 (12.7) 37.9 13.8) 2032 (1158) 1614 (1158)
38.3 (9.9) 38.9 (10.2) 1947 (1604) 1269 (836)
is date.
s CHF Dementia Type 2
diabetes
Diabetic
retinopathy
Deep vein
thrombosis
0.865 0.810 0.939 0.977 0.980
0.885 0.810 0.945 0.988 0.965
0.875 0.850 0.945 0.988 0.949
0.875 0.834 0.945 0.988 0.949
0.875 0.807 0.945 0.988 0.981
0.831 0.858 0.919 0.952 0.990
0.855 0.936 0.926 0.976 0.954
0.811 0.859 0.949 0.989 0.949
0.881 0.850 0.949 0.989 0.949
0.853 0.917 0.926 0.976 0.990
0.980 0.858 1.000 1.000 0.910
0.980 0.822 1.000 1.000 0.870
0.875 0.850 0.945 0.988 0.949
0.875 0.834 0.945 0.988 0.960
0.967 0.838 1.000 1.000 0.912
0.900 0.858 0.958 0.976 0.947
0.914 0.894 0.961 0.988 0.940
0.871 0.854 0.944 0.988 0.949
0.871 0.840 0.944 0.988 0.960
0.871 0.818 0.944 0.988 0.980
0.825 0.817 0.904 0.991 0.953
0.914 0.831 0.957 0.990 0.971
0.844 0.798 0.913 0.989 0.947
0.844 0.766 0.913 0.989 0.927
0.844 0.755 0.913 0.989 0.955
tion by using the number of correctly classiﬁed positive and negative validation
e));
(after) + POS(before) + FP(after)).
Fig. 4. A comparison between all machine learning approaches by phenotype using receiver operator characteristic (ROC) curves. The diabetes retinopathy ROC curves are not
displayed because of the similarity between each machine learning approach. Overall, the pictured models were very similar with ILP + BP ROC showing the best results for
congestive heart failure, deep vein thrombosis and type 2 diabetes.
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Table 4
Combined phenotype validation results.
ILP-1a ILP + BPb PARTc J48d JRIPe
Accuracy 0.878 0.912 0.886 0.883 0.895
Precision 0.897 0.895 0.893 0.893 0.904
Recall 0.860 0.940 0.880 0.880 0.890
F-Measure 0.876 0.917 0.889 0.886 0.895
Bolded numbers indicate highest score between phenotyping methods.
Note: The results from a binomial classiﬁcation (counting # wins for each method
by phenotype), then using a two-sided sign test (binomial distribution test) at 95%
conﬁdence to determine if there is a difference. There was a signiﬁcant difference
favoring ILP + BP when compared to PART (p = 0.039), J48 (p = 0.003) and JRIP
(p = 0.003) when evaluating AUROC. There was no signiﬁcant difference when
testing accuracy, precision, recall, and F-Measure.
a ILP-1: inductive logic programming with using POS(after)  (NEG(after) +
POS(before)).
b ILP + BP: inductive logic programming + borderline positives using POS(after) 
(NEG(after) + POS(before) + FP(after)).
c PART: Java implementation of a rule based classiﬁer in WEKA.
d J48: Java implementation of C4.5 classiﬁer available in WEKA.
e JRIP: Java implementation of RIPPER rule-based classiﬁer available in WEKA.
Table 5
Comparison of eMERGE phenotyping model precision to ILP + BP.
eMERGEa eMERGE at Marshﬁeld ILP + BPd
Cataract 0.960–0.977 0.956b 0.877
Dementia 0.730–0.897 0.897c 0.936
Type 2 diabetes 0.982–1.000 0.990c 0.926
Diabetic retinopathy 0.676–0.800 0.800c 0.976
a eMERGE precision range taken from Table 3 in Newton et al. [6]. The range
represents multiple eMERGE institution precision estimates.
b Precision for Marshﬁeld eMERGE cohort indicating the combined cohort pre-
cision deﬁnition in Peissig et al. [28].
c eMERGE precision for Marshﬁeld taken from Table 3 in Newton et al. [6].
d LP + BP: inductive logic programming + borderline positives taken from Table 3.
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surements for each ML approach (ILP-1, ILP + BP, PART, J48, and
JRIP) appearing in Table 3. Type 2 diabetes, diabetic retinopathy,
and deep vein thrombosis phenotypic models consistently had
high performance statistics (>0.900 in all categories) across all
ML approaches. Acute liver injury had the lowest performance
measurements for all ML approaches. There was no signiﬁcant dif-
ference in overall accuracy between ILP-1 and ILP + BP models,
although ILP-1 performed signiﬁcantly better than ILP + BP in
detecting POS examples (p = 0.0006), and ILP + BP performed sig-
niﬁcantly better than ILP-1 when detecting NEG examples
(p = 0.008). The addition of BP examples had the desired effect of
increasing precision, but at the cost of decreased recall when com-
paring ILP-1 with ILP + BP.
Fig. 4 presents ROC curves for eight of the nine phenotypes.
Shown on each plot are the ROC curves for each ML approach
(ILP-1, ILP + BP, J48, PART, JRIP). The diabetic retinopathy ROC
curves looked similar between all models and are not displayed
because of space limitations. The pictured ROC curves suggest sub-
stantial improvement over chance assignment (indicated by the
reference line), with generally similar results among approaches.
ILP + BP appeared to outperform the other ML approaches for the
congestive heart failure, deep vein thrombosis, and type 2 diabetes
phenotypes. These plots combined with the summary statistics
presented in Tables 3 and 4 provide an understanding of how the
model results compare across phenotypes.
An overall comparison of machine learning approaches is pre-
sented in Table 4. There was no signiﬁcant difference in overall
accuracy, precision, recall, or F-Measure between the ML
approaches. When comparing AUROC for ILP + BP to PART, J48,
and JRIP, ILP + BP performed signiﬁcantly better than PART
(p = 0.039), J48 (p = 0.003), and JRIP (p = 0.003).
4. Discussion
In this study, we used a de-identiﬁed version of EHR coded data
to construct phenotyping models for nine different phenotypes. All
ML approaches used ICD-9-CM diagnostic codes to deﬁne training
cases and controls (POS, NEG, and BP examples) for the supervised
learning task. We developed ILP models (either ILP-1 or ILP + BP)
that produced F-measure metrics for six of nine phenotypes that
exceeded 0.900, which is comparable to other phenotyping inves-
tigations [38–41]. For example, the type 2 diabetes phenotype was
also studied by Dingcheng et al. [11], where they reported an
F-measure of 0.914; we achieved an F-measure of 0.958 (ILP-1)
and 0.961 (ILP + BP), albeit on different validation data.Several of the phenotypes selected for use in this research (type
2 diabetes, diabetic retinopathy, dementia, and cataracts), corre-
sponded to phenotypes used by the Electronic Medical Records
and Genomics (eMERGE) network [42] for genome-wide associa-
tion studies [6,28,38]. The eMERGE phenotyping models used a
variety of EHR data, were developed using a multi-disciplinary
team approach, and each phenotyping model took many months
to construct and validate. Our method used similar coded EHR
data, required minimum effort from the multi-disciplinary team,
and developed phenotype models in a few days; however, our
development relied on testing cohorts. The ILP phenotyping mod-
els were comparable in precision (also referred to as positive pre-
dictive value) for three of the four phenotypes when compared to
eMERGE network algorithms (refer to Table 5) [6,28,38]. We would
expect similar precision rates between eMERGE-Marshﬁeld and
the ILP + BP approaches due to the overlap of patients in the testing
cohorts and using similar EHR data. Possible reasons for the differ-
ences between eMERGE and ILP + BP precision could be sample dif-
ferences and size. For example, the eMERGE cataract cohort had
4309 cataract cases used to calculate precision and our study had
244 cases (we selected a sample of the cases from the eMERGE
cohort).
An advantage of using ILP is that the ILP rules reﬂect character-
istics of patient subgroups for a phenotype. The ILP rules can be
easily interpreted by a physician (or others) to identify relevant
model features that not only identify patients, but also discrimi-
nate between patients that should or should not be classiﬁed as
cases. In addition, ILP rules are learned from the EHR database.
These rules are not based on human intuition or ‘‘ﬁltered’’ because
of preconceived opinions about a phenotype. To emphasize the
later point, our physician author (MC) evaluated the ILP + BP rules
for acute liver injury in Table 6 and questioned why high levels of
‘‘Differential Nucleated RBC’’ surfaced in Rule #35. After research, a
mechanism for a sudden rise in nucleated red cells was found in
the association with injury to hepatic and bone marrow sinusoidal
endothelium as part of the fetal response to hypoxia or partial
asphyxia [43]. This example provides some evidence that one’s
existential biases can hide relevant information. This relevant
information could be used to improve a phenotype model.
Initially, we used a simple scoring function that evaluated
the differences between the POS and NEG examples using
data captured after the initial diagnosis for both groups
(POS(after)  NEG(after)). We then tried to improve model accuracy
by adding the before data for POS patients and after data for the
BP patients; the goal of these additions was to mute some of the
features that were common between true positive and false posi-
tive examples, thus making the model more discriminatory. Given
the high recall and precision of our method, in either case only a
few EHR-driven models yielded substantially different classiﬁca-
tions between the two approaches, making it difﬁcult to demon-
strate that there is a difference in model performance when
adding the BP(after) and POS(before) data. We speculate that larger
phenotype testing sets may allow one to see a difference if it exists.
Table 6
Top eight ‘‘scoring’’ inductive logic programming (ILP + BP) rules for acute liver injury.
Rule
#
POS
Covera
NEG
Coverb
ILP + BP Rule Probabilityc
30 95 0 diagnoses(A,B,C,’790.4’,’Elev Transaminase/Ldh’,D), lab(A,E,20719,’Urea Nitrogen Bld’,F,’Normal’), lab(A,E,20727,’Alkaline
Phosphatase (T-Alkp)’,G,’High’)
1.00
35 52 0 has_tx(A,B,’99232’,’Sbsq Hospital Care/Day 25 Minutes’,C,D,E,F), lab(A,B,20816,’Differential Nucleated RBC’,G,’High’) 1.00
42 129 0 diagnoses(A,B,C,’782.4’,’Jaundice Nos’,D), lab(A,E,20727,’Alkaline Phosphatase (T-Alkp)’,F,’High’) 1.00
72 113 0 has_tx(A,B,’99214’,’Ofﬁce Outpatient Visit 25 Minutes’,C,D,E,F), lab(A,G,20809,’Differential Segment Neut-Segs’,H,’Normal’),
lab(A,G,20728,’Bilirubin’,F,’High’)
1.00
3 146 1 lab(A,B,20728,’Bilirubin Total’,C,’High’), lab(A,D,20900,’Direct Bilirubin’,E,’High’), lab(A,F,20857,’Red Cell Distribute
Width(RDW)’,G,’High’)
0.99
51 142 1 lab(A,B,20900,’Direct Bilirubin’,C,’High’), lab(A,B,20719,’Urea Nitrogen Bld’,D,’Normal’), lab(A,B,20731,’AST (GOT)’,E,’High’) 0.99
11 138 1 lab(A,B,20728,’Bilirubin Total’,C,’High’), lab(A,B,20809,’Differential Segment Neut-Segs’,D,’Normal’),
lab(A,E,20282,’Glucose’,F,’High’)
0.99
60 137 1 lab(A,B,20715,’Potassium (K)’,C,’Normal’), lab(A,B,20727,’Alkaline Phosphatase (T-Alkp)’,D,’High’),
lab(A,E,20901,’Unconjugated Bilirubin’,F,’High’)
0.99
Note: The ILP + BP rules can be easily interpreted by a human with little training. The ‘‘bold’’ lettered rules are indicative of ‘‘facts’’ related to or associated with acute liver
injury. The highlighted ILP + BP rule (rule #35) represents a ‘‘fact’’ (Differential Nucleated RBC’ is ‘High’) that was unknown to a physician reviewer prior to this investigation.
Fifty-two POS subjects were classiﬁed in the training set using rule #35.
a Represents the number of positive examples covered by the rule.
b Represents the number of negative examples covered by the rule.
c Probability = POS examples/(POS examples + NEG examples).
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studied.
ILP provides a series of rules that identify patients with a given
phenotype. Most of the rules include a diagnostic code (suspected
because POS selection of training subjects was based on diagnostic
codes) along with one or more other features. We noticed that in
some situations, ILP would learn a rule that was too general and,
thus, invite the identiﬁcation of false positives. Future research is
needed to examine grouping of rules and selection of subjects
based on a combination of rule conditions, thereby combining
the advantages of ILP and the general ‘‘rule-of-N’’ approach com-
monly used in phenotyping which states a unique event must be
present on ‘‘N’’ days to determine a case/control.
This study has several limitations. First, the study used only
structured or coded data found within the EHR for phenotyping
[7,44]. Other studies have indicated that clinical narratives and
images provide more speciﬁc information to reﬁne phenotyping
models [9,28,44]. We envision use of natural language processing
and/or optical character recognition techniques as tools to increase
the availability of EHR structured data and, thus, hypothesize that
using such data will improve most ML phenotyping approach
results as noted by Saria et al. [45]. Second, a single EHR and insti-
tution was used in this research, thus limiting the generalizability
of the study results. We attempted to improve generalizability of
this research by using multiple phenotypes representing both
acute and chronic conditions. More research is needed to apply
these approaches across several institutions and EHRs. Third, using
15-20 ICD-9 to identify POS examples can be problematic for some
diseases/conditions. For example, a patient with 20+ deep vein
thrombosis (DVT) ICD-9 codes may not have the same disease as
a patient with only a single DVT code. More research is needed
to investigate robust ways to identify POS examples for phenotype
model building. Finally, we demonstrated ILP using relatively com-
mon diseases that were selected based on the availability of exist-
ing validation or testing cohorts. ILP did not perform well on acute
conditions. For example, the performance measurements for acute
liver injury were lower than many of the chronic diseases pheno-
types presented in Table 3. More research is needed to evaluate
ILP for acute, rare, and longitudinal phenotypes.
5. Conclusion
We believe that our research has the potential to address sev-
eral challenges of using the EHR for phenotyping. First, we showedpromising results for ILP as a viable EHR-based phenotyping
approach. Second, we introduced novel ﬁltering techniques and
infused BPs into training sets to improve ILP, suggesting that this
practice could be used to inform other ML approaches. Third, we
showed that labeling examples as ‘positive’ based on having multi-
ple occurrences of a diagnosis can potentially reduce the amount of
expert time needed to create training sets for phenotyping. Finally,
the human-interpretable phenotyping rules created from ILP could
conceivably identify important clinical attributes missed by other
methods, leading to reﬁned phenotyping models.Contributorship
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